Assessments
Tumors
TUMORS, EVENT
The primary endpoint was margin‐negative (R0) resection, defined by clear surgical margins of at least 1 mm, among all enrolled patients.All participants had contrast‐enhanced CT chest, abdomen, and pelvis completed at baseline, many of whom had dedicated multiphase pancreas protocol, but this was not required per protocol. Subsequent contrast‐enhanced CT scans were obtained after two cycles of gemcitabine and nab‐paclitaxel, after chemoradiation, and after surgery before subsequent four cycles of chemotherapy. Radiographic response was evaluated using revised Response Evaluation Criteria in Solid Tumors (RECIST) guideline (version 1.1),All participants had at least 1‐year follow‐up after surgery if they were still alive and remained in the clinical trial. After completion of all therapies, patients underwent surveillance with CA19‐9 and contrast CT scans approximately every 3 months until an event of interest or end of follow‐up. Many patients had longer follow‐up.